⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

June 9, 2026Neurology

Targeting B-cell Signaling in Multiple Sclerosis: A Meta-analysis of Bruton’s Tyrosine Kinase (BTK) Inhibitors (P4-18.001)

Hira Zafar Hafiz Talha Javed Muhammad Hassan Akhtar Ali Hamdan Alishba Ehtisham Z. Jamshaid Eiman Ijaz Aina Ashfaq Hafsah Gulzar Huda Afzal Muhammad Qasim Qureshi

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research aims to evaluate how effective Bruton’s Tyrosine Kinase inhibitors are in treating Multiple Sclerosis.
Conducted a meta-analysis of relevant studies on BTK inhibitors for MS treatment.
Searched electronic databases for trials involving BTK inhibitors and MS.
Assessed the efficacy of BTK inhibitors using statistical measures.
BTK inhibitors showed a significant reduction in disease activity in MS patients (exact rates not provided).
Efficacy varied across studies, suggesting potential benefits depending on specific circumstances.

Implication

Meta-analysis evaluates BTK inhibitors' efficacy in multiple sclerosis, suggesting potential therapeutic implications.

Abstract

To evaluate the efficacy of Bruton’s Tyrosine Kinase (BTK) inhibitors in the treatment of Multiple Sclerosis (MS).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Zafar et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf393faef96ed7f056133 https://doi.org/10.1212/wnl.0000000000213297

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Bruton’s Tyrosine Kinase Inhibitors in Multiple Sclerosis: A Meta-analysis With Reconstructed Individual Patient Data (P4-20.010)Meta-Analysis · 2026
2Bruton’s Tyrosine Kinase Inhibitors in Multiple SclerosisLate-Phase Clinical Trial · 2026 · 2 citations
3Emerging Role of BTK Inhibitors in Multiple Sclerosis: From Immunobiology to Clinical TranslationRCT · 2026
4Bruton’s tyrosine kinase inhibitors in brain diseases2024
5Bruton’s Tyrosine Kinase Inhibitors in Multiple Sclerosis: Mechanistic Considerations Across Relapsing and Progressive DiseaseEarly-Phase Clinical Trial · 2026